Article Summary

This article covers a court decision that restricts access to the abortion pill mifepristone by reinstating an old rule requiring in-person pickup, which critics say undermines FDA authority and threatens telemedicine abortion access. It highlights concerns from drug makers and medical supporters who argue the move is driven by anti-abortion ideology rather than scientific or medical evidence. The ruling is portrayed as a major setback for abortion access since the fall of Roe v. Wade.